Udvalget for Humanmedicinske Lægemidler (CHMP) har konkluderet, at fordelene ved Ovitrelle er større end risiciene for kvinder med behov for ovulation forud for fertilitetsbehandling og for kvinder, der er anovulatoriske eller oligo- ovulatoriske.
The Committee for Medicinal products for Human Use (CHMP) decided that Ovitrelle’ s benefits are greater than its risks for women who need to ovulate before fertility treatment and in women who are anovulatory or oligo-ovulatory.